Clinical Trial Update: A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib [Phase 2]

View source ↗

Summary

Phase II pediatric study evaluating dasatinib for newly diagnosed chronic phase chronic myeloid leukemia or Philadelphia chromosome-positive leukemias resistant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome-positive Leukemias

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-01-05